[{"abstract": "Layoffs, falling stock and slim dividends leave Pfizer little to cheer about one day after the $68 billion megamerger with Wyeth.", "web_url": "https://www.nytimes.com/2009/01/27/business/27chief.html", "snippet": "Layoffs, falling stock and slim dividends leave Pfizer little to cheer about one day after the $68 billion megamerger with Wyeth.", "lead_paragraph": "After announcing the $68 billion megamerger with Wyeth on Monday morning, Pfizer\u2019s chief executive, Jeffrey B. Kindler, did not have much time to celebrate.", "print_section": "B", "print_page": "1", "source": "The New York Times", "multimedia": [], "headline": {"main": "For Pfizer, a Big Deal and a Test", "kicker": null, "content_kicker": null, "print_headline": "For Pfizer, A Big Deal And a Test", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 1, "major": "N"}, {"name": "subject", "value": "Company Reports", "rank": 2, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc", "rank": 3, "major": "N"}, {"name": "subject", "value": "Layoffs and Job Reductions", "rank": 4, "major": "N"}, {"name": "subject", "value": "Medicine and Health", "rank": 5, "major": "N"}, {"name": "persons", "value": "Kindler, Jeffrey B", "rank": 6, "major": "N"}, {"name": "organizations", "value": "Wyeth", "rank": 7, "major": "N"}], "pub_date": "2009-01-27T03:06:55+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Duff Wilson", "person": [{"firstname": "Duff", "middlename": null, "lastname": "Wilson", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/ff168fe6-4a32-5e1d-992e-6558e8108857", "word_count": 1248, "uri": "nyt://article/ff168fe6-4a32-5e1d-992e-6558e8108857"}, {"abstract": "Pfizer\u2019s move to buy Wyeth dims the hopes of struggling small biotechnology companies that wanted to sell themselves or their products to larger businesses.", "web_url": "https://www.nytimes.com/2009/01/27/business/27biotech.html", "snippet": "Pfizer\u2019s move to buy Wyeth dims the hopes of struggling small biotechnology companies that wanted to sell themselves or their products to larger businesses.", "lead_paragraph": "This month Pfizer\u2019s chief executive, Jeffrey B. Kindler, held a breakfast for venture capitalists atop a hotel in San Francisco. Some guests took it as a sign that Pfizer was serious about buying young biotechnology companies or licensing their technology. ", "print_section": "B", "print_page": "4", "source": "The New York Times", "multimedia": [], "headline": {"main": "Wyeth Deal May Slow Pfizer Biotech Acquisitions", "kicker": null, "content_kicker": null, "print_headline": "Purchase of Wyeth May Blunt Pfizer\u2019s Appetite for Small Biotech Companies", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 1, "major": "N"}, {"name": "organizations", "value": "Biogen Idec Incorporated", "rank": 2, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc", "rank": 3, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 4, "major": "N"}, {"name": "organizations", "value": "AMGEN INC", "rank": 5, "major": "N"}, {"name": "organizations", "value": "Wyeth", "rank": 6, "major": "N"}, {"name": "subject", "value": "Biotechnology", "rank": 7, "major": "N"}], "pub_date": "2009-01-27T03:11:40+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Andrew Pollack", "person": [{"firstname": "Andrew", "middlename": null, "lastname": "Pollack", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/29a4957d-5eb7-5270-bff9-2bfccdfaa96a", "word_count": 872, "uri": "nyt://article/29a4957d-5eb7-5270-bff9-2bfccdfaa96a"}, {"abstract": "Molecules.", "web_url": "https://dealbook.nytimes.com/2009/01/27/in-wyeth-pfizer-sees-a-drug-pipeline/", "snippet": "", "lead_paragraph": "Molecules.", "source": "The New York Times", "multimedia": [], "headline": {"main": "In Wyeth, Pfizer Sees a Drug Pipeline", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [], "pub_date": "2009-01-27T11:59:48+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Dealbook", "person": [{"firstname": "Dealbook", "middlename": null, "lastname": "", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/b010c051-b9a4-5e3b-9e87-bf571e1974bb", "word_count": 1093, "uri": "nyt://article/b010c051-b9a4-5e3b-9e87-bf571e1974bb"}, {"abstract": "After announcing the $68 billion megamerger with Wyeth on Monday morning, Pfizer\u2019s chief executive, Jeffrey B. Kindler, did not have much time to celebrate.", "web_url": "https://dealbook.nytimes.com/2009/01/27/for-pfizer-a-big-deal-and-a-test/", "snippet": "", "lead_paragraph": "After announcing the $68 billion megamerger with Wyeth on Monday morning, Pfizer\u2019s chief executive, Jeffrey B. Kindler, did not have much time to celebrate.", "source": "The New York Times", "multimedia": [], "headline": {"main": "For Pfizer, a Big Deal and a Test", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [], "pub_date": "2009-01-27T12:01:05+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Dealbook", "person": [{"firstname": "Dealbook", "middlename": null, "lastname": "", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/4ab64c82-ca65-5044-ac9e-9d1043e93d36", "word_count": 1222, "uri": "nyt://article/4ab64c82-ca65-5044-ac9e-9d1043e93d36"}, {"abstract": "This month Pfizer\u2019s chief executive, Jeffrey B. Kindler, held a breakfast for venture capitalists atop a hotel in San Francisco. Some guests took it as a sign that Pfizer was serious about buying young biotechnology companies or licensing their technology.", "web_url": "https://dealbook.nytimes.com/2009/01/27/wyeth-deal-may-slow-pfizer-biotech-acquisitions/", "snippet": "", "lead_paragraph": "This month Pfizer\u2019s chief executive, Jeffrey B. Kindler, held a breakfast for venture capitalists atop a hotel in San Francisco. Some guests took it as a sign that Pfizer was serious about buying young biotechnology companies or licensing their technology.", "source": "The New York Times", "multimedia": [], "headline": {"main": "Wyeth Deal May Slow Pfizer Biotech Acquisitions", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [], "pub_date": "2009-01-27T12:10:58+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Dealbook", "person": [{"firstname": "Dealbook", "middlename": null, "lastname": "", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/1fc7fe3f-c92e-5298-9a5f-e1602e186ea5", "word_count": 869, "uri": "nyt://article/1fc7fe3f-c92e-5298-9a5f-e1602e186ea5"}]